Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bug

Showing results (191-200 of 319) with videos related to

Pageof 32
Sort By:
Leukemia|January 15, 2013
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantationT Schroeder, A Czibere, U Platzbecker, et al.
Leukemia & Lymphoma|March 22, 2026
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphomaClara Walter, Michael C Burger, Kai Siebenbrodt, et al.
Neuroinformatics|October 30, 2008
Federated access to heterogeneous information resources in the Neuroscience Information Framework (NIF)Amarnath Gupta, William Bug, Luis Marenco, et al.
Frontiers in Immunology|March 21, 2022
Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following TisagenlecleucelAndreas Peinelt, Melanie Bremm, Hermann Kreyenberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2018
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter StudyPatrizia Chiusolo, Gesine Bug, Attilio Olivieri, et al.
British Journal of Haematology|September 17, 2013
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemiaCarsten Müller-Tidow, Gesine Bug, Michael Lübbert, et al.
European Journal of Immunology|April 7, 2022
SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccinationAndrea Jarisch, Eliza Wiercinska, Shabnam Daqiq-Mirdad, et al.
Plos One|March 17, 2021
High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndromeIvan Sergeevich Moiseev, Nikolay Yurevich Tcvetkov, Ildar Munerovich Barkhatov, et al.
Leukemia|January 29, 2013
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I studyU Platzbecker, F Braulke, A Kündgen, et al.
Oncotarget|August 21, 2018
Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker developmentJulia Schueler, Kerstin Klingner, Daniel Bug, et al.
Pageof 32

Showing results (191-200 of 319) with videos related to

Sort By:
Pageof 32
Leukemia|January 15, 2013
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantationT Schroeder, A Czibere, U Platzbecker, et al.
Leukemia & Lymphoma|March 22, 2026
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphomaClara Walter, Michael C Burger, Kai Siebenbrodt, et al.
Neuroinformatics|October 30, 2008
Federated access to heterogeneous information resources in the Neuroscience Information Framework (NIF)Amarnath Gupta, William Bug, Luis Marenco, et al.
Frontiers in Immunology|March 21, 2022
Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following TisagenlecleucelAndreas Peinelt, Melanie Bremm, Hermann Kreyenberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2018
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter StudyPatrizia Chiusolo, Gesine Bug, Attilio Olivieri, et al.
British Journal of Haematology|September 17, 2013
A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemiaCarsten Müller-Tidow, Gesine Bug, Michael Lübbert, et al.
European Journal of Immunology|April 7, 2022
SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccinationAndrea Jarisch, Eliza Wiercinska, Shabnam Daqiq-Mirdad, et al.
Plos One|March 17, 2021
High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndromeIvan Sergeevich Moiseev, Nikolay Yurevich Tcvetkov, Ildar Munerovich Barkhatov, et al.
Leukemia|January 29, 2013
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I studyU Platzbecker, F Braulke, A Kündgen, et al.
Oncotarget|August 21, 2018
Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker developmentJulia Schueler, Kerstin Klingner, Daniel Bug, et al.
Pageof 32